Pharming Adds CDZ173 To Its Rare Disease Pipeline, Foresees Launch by 2022
The Dutch rare disease group says licensing CDZ173 from Novartis is Pharming’s first step towards building off the commercial success of its sole product, Ruconest, in HAE.
You may also be interested in...
Pharming Leniolisib Launch Will Require Identifying Patients With Ultra Rare APDS
The company sees leniolisib as a way to expand its US and global commercial footprint before bringing in additional rare disease assets.
Pharming’s Leniolisib On Track To Become First Disease-Modifying APDS Drug
The Dutch firm’s US filing for its first-in-class PI3K inhibitor has been accepted under priority review, bringing the asset closer to becoming the first disease-modifying option for a rare, genetic disorder.
Pharming To Branch Out Into Japan With Leniolisib Following Successful Pivotal Trial
The Dutch firm has announced its intention to submit US and EU filings for leniolisib and expand development into Japan after the candidate impressed in an ultra-rare disease study.